Brune Jakob E, Dickenmann Michael, Sidler Daniel, Walti Laura N, Golshayan Déla, Manuel Oriol, Haidar Fadi, Neofytos Dionysios, Schnyder Aurelia, Boggian Katia, Mueller Thomas F, Schachtner Thomas, Khanna Nina, Schaub Stefan, Wehmeier Caroline
Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
Clinic for Nephrology, Bern University Hospital, Bern, Switzerland.
Front Med (Lausanne). 2024 Feb 15;11:1329778. doi: 10.3389/fmed.2024.1329778. eCollection 2024.
are often responsible for urinary tract infection (UTI) in kidney transplant recipients. Among these, or producing extended-spectrum beta-lactamase (ESBL) are emerging. However, there are only scarce data on frequency and impact of ESBL-UTI on transplant outcomes.
We investigated frequency and impact of first-year UTI events with ESBL and/or in a prospective multicenter cohort consisting of 1,482 kidney transplants performed between 2012 and 2017, focusing only on 389 kidney transplants having at least one UTI with and/or . The cohort had a median follow-up of four years.
In total, 139/825 (17%) first-year UTI events in 69/389 (18%) transplant recipients were caused by ESBL-producing strains. Both UTI phenotypes and proportion among all UTI events over time were not different compared with UTI caused by non-ESBL-producing strains. However, hospitalizations in UTI with ESBL-producing strains were more often observed (39% versus 26%, = 0.04). Transplant recipients with first-year UTI events with an ESBL-producing strain had more frequently recurrent UTI (33% versus 18%, = 0.02) but there was no significant difference in one-year kidney function as well as longer-term graft and patient survival between patients with and without ESBL-UTI.
First-year UTI events with ESBL-producing and/or are associated with a higher need for hospitalization but do neither impact allograft function nor allograft and patient survival.
肾移植受者的尿路感染（UTI）通常由[具体细菌名称1]或[具体细菌名称2]引起。其中，产超广谱β-内酰胺酶（ESBL）的[具体细菌名称1]或[具体细菌名称2]正在出现。然而，关于ESBL-UTI的发生率及其对移植结局影响的数据却很少。
我们在一个前瞻性多中心队列中调查了2012年至2017年间进行的1482例肾移植受者中，第一年发生的由产ESBL的[具体细菌名称1]和/或[具体细菌名称2]引起的UTI事件的发生率及其影响，仅关注389例至少发生过一次由[具体细菌名称1]和/或[具体细菌名称2]引起的UTI的肾移植受者。该队列的中位随访时间为4年。
在69/389（18%）例移植受者中，共有139/825（17%）例第一年UTI事件是由产ESBL的菌株引起的。与非产ESBL菌株引起的UTI相比，UTI的表型以及所有UTI事件随时间的比例并无差异。然而，产ESBL菌株引起的UTI患者住院情况更为常见（39%对26%，P = 0.04）。第一年发生由产ESBL菌株引起的UTI事件的移植受者复发性UTI更为频繁（33%对
